Compare WDFC & ZLAB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | WDFC | ZLAB |
|---|---|---|
| Founded | 1953 | 2013 |
| Country | United States | China |
| Employees | N/A | N/A |
| Industry | Major Chemicals | Biotechnology: Pharmaceutical Preparations |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.7B | 2.6B |
| IPO Year | 1995 | 2017 |
| Metric | WDFC | ZLAB |
|---|---|---|
| Price | $219.25 | $21.06 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 4 | 12 |
| Target Price | ★ $254.00 | $34.21 |
| AVG Volume (30 Days) | 96.3K | ★ 1.1M |
| Earning Date | 01-07-2027 | 11-05-2026 |
| Dividend Yield | ★ 1.85% | N/A |
| EPS Growth | N/A | ★ 38.46 |
| EPS | ★ 6.08 | N/A |
| Revenue | ★ $488,109,000.00 | $460,156,000.00 |
| Revenue This Year | $5.78 | N/A |
| Revenue Next Year | $5.25 | $22.47 |
| P/E Ratio | $36.21 | ★ N/A |
| Revenue Growth | ★ 19.49 | 15.33 |
| 52 Week Low | $175.38 | $15.96 |
| 52 Week High | $298.90 | $29.02 |
| Indicator | WDFC | ZLAB |
|---|---|---|
| Relative Strength Index (RSI) | 51.06 | 36.38 |
| Support Level | $199.17 | $17.35 |
| Resistance Level | $226.33 | $26.64 |
| Average True Range (ATR) | 5.76 | 1.37 |
| MACD | -1.05 | -0.33 |
| Stochastic Oscillator | 10.40 | 10.89 |
WD-40 Co is a global marketing organization focused on developing and selling products that solve maintenance and cleaning problems internationally. It offers two product groups: maintenance products, including the flagship WD-40 Multi-Use Product, which serves as a lubricant, rust preventative, penetrant, and moisture displacer, marketed globally; and homecare and cleaning products, mainly sold in North America, the UK, and Australia. The company distributes its products through hardware stores, automotive parts outlets, industrial suppliers, mass retailers, online platforms, and specialty retailers across the Americas, EIMEA, and Asia-Pacific, with the majority of revenue generated in the Americas.
Zai Lab Ltd is a biopharmaceutical company focusing on discovering or licensing, developing, and commercializing proprietary therapeutics that address areas of unmet medical need including in the fields of oncology, autoimmune and infectious diseases. Zai Lab has a diverse pipeline of potentially first-in-class product candidates developed through in-house R&D and global partnerships. The company has successfully commercialized several products in China, including Zejula, Optune, Qinlock, and Nuzyra, with plans for further expansion The pipeline of proprietary drug candidates of the company includes ZL-1222, ZL-1311, ZL-6201 and many others.